

6. Can we find molecular markers for drug resistance in *L. infantum* and *Viannia*, and can we show how drug resistance emerges and spreads?
7. We will establish: a) an expanded cryobank, in FIOCRUZ, and
b) a database for project outputs.
8. We will undertake a KAP study in endemic areas to assess how control can be improved.

LeishEpiNetSA: some early outputs (period 1):

Good partnership and steering group established.

- Panel of reference strains assembled.
- Free exchange of methodologies.
- More than 10 MLST targets amplified, subset of further 10 targets under investigation.
- A panel of 14 new MLMT targets selected for the subgenus *Viannia*.
- Comparative MLMT analysis of European *L. infantum* and >40 isolates of *L. infantum* from South America.
- An extensive range of field isolates assembled.
- Collaboration in progress with the *Leishmania*/HIV coinfection network.
- Treatment outcome linked to *Viannia* infecting species (*L. braziliensis*).
- Cryobank database designed in Rio de Janeiro; website agreed for Rio.
- KAP studies well under way in Venezuela, Paraguay, Peru, initiated in Brazil.

The LeishEpiNetSA Partners

No.	Name	Short name	Country
1	London School of Hygiene and Tropical Medicine	LSHTM	UK
2	Universitaetsmedizin Berlin	CUMB	Germany
3	Instituto de Salud Carlos III	ISCHII	Spain
4	Prins Leopold Instituut voor Tropische Geneeskunde	ITG	Belgium
5	Universidade Nova de Lisboa	IHMT	Portugal
6	Universidade Federal do Piaui	UFPI/LIB	Brazil
7	Universidad Nacional de Asuncion	IICS	Paraguay
8	Universidad Peruana Cayetano Heredia	IMTAvH	Peru
9	Unversidade Federal de Minas Gerais	UFMG	Brazil
10	Universidad de Carabobo	UC_BIOMED-CNRFV	Venezuela
11	Fundacao Oswaldo Cruz	Fiocruz-IOC	Brazil
12	Bernhard Nocht Institute for Tropical Medicine	BNI	Germany